Merz Aesthetics

merzaesthetics.com

Merz Aesthetics
At Merz Aesthetics, we have a long history of empowering health care professionals, patients and employees to live every day with confidence. We are known for our clinically-proven and category-leading injectables,

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

news image

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More

CONCERTAI NAMES CLAUDIO D'AMBROSIO, PHD, AS HEAD OF BIOPHARMA PARTNERSHIPS AND RWE SOLUTIONS

Prnewswire | September 10, 2020

news image

ConcertAI has hired Claudio D'Ambrosio, PhD, as head of biopharma partnerships and real-world evidence Solutions. Claudio brings over 15 years of experience as a cancer researcher, commercial leader, and strategic scientific partner to the life sciences industry to help advance the goals of ConcertAI of bringing rapid innovation and precision real-world evidence oncology to the world's top global pharmaceutical companies. ConcertAI is a fast-growing company with the leading technology fo...

Read More

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

news image

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More

Business Insights

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

news image

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More
news image

Business Insights

NEXTRNA LAUNCHES WITH $56 MILLION IN FUNDING TO BRING TRANSFORMATIVE NON-CODING RNA-DIRECTED MEDICINES TO PATIENTS

NextRNA Therapeutics | March 02, 2022

NextRNA Therapeutics, a biotechnology company unlocking the potential of non-coding RNAs to develop transformative therapeutics, announces its launch with $9.3 million in seed financing and a $46.8 million Series A led by Cobro Ventures and Lightchain Capital, with additional participation from Circle Alternative Investments, Evans Capital, Jefferies, Rivas Capital, and Willett Advisors. Proceeds will be used by the company to augment its target and drug discovery engine, expand its pipeline, an...

Read More
news image

CONCERTAI NAMES CLAUDIO D'AMBROSIO, PHD, AS HEAD OF BIOPHARMA PARTNERSHIPS AND RWE SOLUTIONS

Prnewswire | September 10, 2020

ConcertAI has hired Claudio D'Ambrosio, PhD, as head of biopharma partnerships and real-world evidence Solutions. Claudio brings over 15 years of experience as a cancer researcher, commercial leader, and strategic scientific partner to the life sciences industry to help advance the goals of ConcertAI of bringing rapid innovation and precision real-world evidence oncology to the world's top global pharmaceutical companies. ConcertAI is a fast-growing company with the leading technology fo...

Read More
news image

HITGEN AND MORPHIC THERAPEUTIC EXTEND DRUG DISCOVERY RESEARCH COLLABORATION TO IDENTIFY SMALL MOLECULE LEADS AGAINST TARGETS

HitGen Inc., Morphic Therapeutic | July 06, 2020

HitGen Inc. announced today that HitGen and Morphic Therapeutic have extended their drug discovery research collaboration to identify small molecule leads against targets specified by Morphic. HitGen’s industry-leading DNA-encoded library (DEL) technology platform includes over 400 billion encoded syntheses of small molecules with drug-like properties, synthesized on chemically-diverse scaffolds. The collaboration is an extension of a previous agreement which identified active lead compoun...

Read More
news image

Business Insights

SIO2 MATERIALS SCIENCE AND DOOSAN CORPORATION ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE MARKET DEVELOPMENT IN ASIA

SiO2 Materials Science | December 27, 2021

Doosan Corporation, founded in 1896, one of South Korea's largest diversified conglomerates, and SiO2 Materials Science, a privately-owned U.S. advanced materials science corporation introducing breakthrough disruptive technology for packaging biological pharmaceuticals and vaccines, announced an exclusive partnership to sell, market, and distribute SIO2's vial, syringes and blood collection tubes in Asia/Oceania. The partnership will focus initially on the pharmaceutical and diagnostics...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us